# Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

> **NCT03375320** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 298 (actual)

## Conditions studied

- Functioning Pancreatic Neuroendocrine Tumor
- Intermediate Grade Lung Neuroendocrine Neoplasm
- Locally Advanced Digestive System Neuroendocrine Neoplasm
- Locally Advanced Digestive System Neuroendocrine Tumor G1
- Locally Advanced Lung Neuroendocrine Neoplasm
- Locally Advanced Pancreatic Neuroendocrine Tumor
- Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm
- Low Grade Lung Neuroendocrine Neoplasm
- Lung Neuroendocrine Tumor
- Lung Neuroendocrine Tumor G2
- Metastatic Digestive System Neuroendocrine Neoplasm
- Metastatic Digestive System Neuroendocrine Tumor G1
- Metastatic Lung Neuroendocrine Neoplasm
- Metastatic Lung Neuroendocrine Tumor
- Metastatic Pancreatic Neuroendocrine Neoplasm
- Metastatic Pancreatic Neuroendocrine Tumor
- Metastatic Thymus Neuroendocrine Neoplasm
- Neuroendocrine Neoplasm
- Neuroendocrine Tumor
- Neuroendocrine Tumor G2
- Non-Functioning Pancreatic Neuroendocrine Tumor
- Pancreatic Serotonin-Producing Neuroendocrine Tumor
- Thymus Neuroendocrine Tumor
- Unresectable Digestive System Neuroendocrine Neoplasm
- Unresectable Digestive System Neuroendocrine Tumor G1
- Unresectable Lung Neuroendocrine Neoplasm
- Unresectable Pancreatic Neuroendocrine Neoplasm
- Unresectable Thymus Neuroendocrine Neoplasm

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Cabozantinib S-malate
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **OTHER:** Placebo Administration
- **OTHER:** Quality-of-Life Assessment
- **PROCEDURE:** X-Ray Imaging

## Key facts

- **NCT ID:** NCT03375320
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-10-26
- **Primary completion:** 2023-08-23
- **Final completion:** 2026-08-19
- **Target enrollment:** 298 (ACTUAL)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03375320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03375320, "Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03375320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*